Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 3
---
000 Keystone Purchase Shares (collectively, the “Prior Registration Statements”). The actual number of shares of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to Keystone under the Keystone Purchase Agreements, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under the Securities Act of 1933, as amended (the “Securities Act”), with the SEC. See “ The Committed Equity Financing” for a description of the Keystone Purchase Agreements and “ Selling Securityholder” for additional information regarding Keystone. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of our Common Stock by Keystone. Additionally, we will not receive any proceeds from the issuance or sale of the Keystone Commitment Shares. We may receive up to $25 million in aggregate gross proceeds from Keystone under the Keystone Purchase Agreements in connection with sales of the shares of our Common Stock to Keystone pursuant to the Keystone Purchase Agreements, including the Old Keystone Purchase Shares and any shares of our Common Stock sold after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold. As of November 24, 2025, there were 172,373,412 shares of Common Stock outstanding on a fully-diluted basis after giving effect to the conversion of all outstanding Preferred Shares (as defined below), the exercise of all outstanding Warrants and options, and options available for issuance pursuant to our 2024 Plan and 2024 ESPP Plan, as amended from time to time, of which 172,241,636 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 729,596,950 shares of our Common Stock offered for resale by Keystone under this prospectus were issued and outstanding as of November 24, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 80.89% of total number of shares of our fully-diluted Common Stock outstanding and approximately 80.90% of the total number of shares of our fully-diluted Common Stock outstanding held by non-affiliates. This prospectus provides you with a general description of such securities and the general manner in which Keystone may offer or sell the securities. More